Zeitschriftenaufsatz | 2026 Open Access

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments

Autor:in

Vieira R.J.; Sousa-Pinto B.; Bousquet J.; Schünemann H.J.; Zuberbier T.; Bognanni A.; Togias A.; Samolinski B.; Valiulis A.; Williams S.; Bedbrook A.; Czarlewski W.; Torres M.J.; Shamji M.H.; Morais-Almeida M.; Canonica G.W.; Vecillas L.d.l.; Dykewicz M.S.; Jacomelli C.; Klimek L.; Leemann L.; Lourenço O.; Papadopoulos N.G.; Pereira A.M.; Savouré M.; Toppila-Salmi S.K.; Ventura M.T.; Yepes-Nuñez J.J.; Cruz A.A.; Ciprandi G.; Gemicioglu B.; Giovannini M.; Gradauskiene B.; Jartti T.; Jeseňák M.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.E.; Latiff A.H.A.; Mohammad Y.; Ohta K.; Mahesh P.A.; Pali-Schöll I.; Pfaar O.; Regateiro F.S.; Roche N.; Taborda-Barata L.; Ulrik C.S.; Viegi G.; Zhang L.; Haahtela T.; Cherrez-Ojeda I.; Ivancevich J.C.; Khaltaev N.; Yorgancioglu A.; Abdullah B.; Al-Ahmad M.; Al-Nesf M.A.; Amaral R.; Asllani J.; Bergmann K.C.; Bernstein J.A.; Blaiss M.S.; Toskala E.; Carreiro-Martins P.; Casale T.; Cecchi L.; Fiocchi A.; Giuliano A.F.M.; Christoff G.; Cirule I.; de Sousa J.C.; Costa E.M.; Devillier P.; Hossny E.; Iinuma T.; Ispayeva Z.; Julge K.; Kaidashev I.; Bennoor K.S.; Kraxner H.; Kull I.; Kulus M.; Kupczyk M.; Kurchenko A.; La Grutta S.; Miculinic N.; Tuyet L.L.T.; Lee S.M.; Montefort S.; Moreira A.; Mullol J.; Nadif R.; Nakonechna A.; Neffen H.E.; Niedoszytko M.; O'Hehir R.E.; Ogulur I.; Okamoto Y.; Olze H.

Publikationen als Autor:in / Herausgeber:in der Vetmeduni

Pali, Isabella

Journal

Allergy

Schlagwörter

allergic rhinitis; guidelines; leukotriene receptor antagonists; ocular antihistamines; oral antihistamines

Dokumententyp

Übersichtsarbeit

CC Lizenz

CC-BY

Open Access Type

Hybrid

ISSN/eISSN

0105-4538 - 1398-9995

DOI

10.1111/all.70305

PubMed ID

41877472

URL

https://onlinelibrary.wiley.com/doi/10.1111/all.70305

Weitere Details

Background: Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)-EAACI guidelines, this manuscript presents the ARIA-EAACI 2024–2025 recommendations for oral and ocular treatments. Methods: The ARIA-EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results: Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion: This ARIA-EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.